The present invention relates to a drug delivery fabric having a drug-containing layer, wherein the drug delivery fabric comprises a surface layer, a middle layer, and a drug-containing layer, the middle layer is formed of a yarn having hydrophilicity relatively equal to or higher than that of the surface layer, the drug-containing layer is formed of a cellulose derivative film containing a drug.

The present invention provides safe and effective methods for the treatment of sialorrhea (excessive drooling) by administering an effective amount of N-desethyloxybutynin, or an optical R- or S-isomer thereof or a pharmaceutically acceptable salt thereof.

Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.

Dosing regimen for transdermal delivery of hormones comprising a monthly treatment cycle with a fixed treatment interval and a variable rest interval.

Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.

Described herein are compositions in nanofiber form including one or more bioactive compounds releasably incorporated thereon. In one embodiment a composition is described comprising at least one nanofiber and at least one bioactive compound. The nanofibers are formed from a base material that is solubilized with the bioactive or bioactives in an aqueous based solvent solution and the base material and bioactives are together spun via electrospinning to form dry fibers with the bioactives chemically bonded to the nanofibers and the bioactives remaining stable during storage of the composition under ambient conditions substantially free of moisture. On exposure to moisture, the nanofibers dissolve, thereby releasing the bioactives.

Pharmaceutical compositions and methods for treating and/or preventing and/or control of Parkinson's Disease and/or related symptoms in a patient.

The present invention relates to the use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase includes the additive and an active agent dissolved therein. The additive has a higher affinity to water than to the active agent and controls the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate being proportional to the amount of active agent in the biphasic layer.

Described herein are silicone-containing acrylic polymers useful, for example, in transdermal drug delivery compositions, to methods of making and using them, to transdermal drug delivery compositions comprising them, and to methods of making and using such transdermal drug delivery compositions. The polymers are particular suitable for formulating amine drugs, such as amphetamine, methylphenidate, rivastigmine, paroxetine and clonidine.

The present invention relates to a high adhesion dermal therapeutic system comprising an adhesive polymeric matrix with a salt of Diclofenac.